Objective The aim of present study was to detect methylation rate of CpG unit of brain derived neurotrophic factor (BDNF) promoter and to study the epigenetic mechanism of autism spectrum disorders (ASD).Methods Total of 12 ASD patients and 12 healthy controls were recruited.The methylation rate of CpG unit in BDNF promoter Ⅰ and Ⅳ were detected using Sequenom MassArray method.The methylation model,correlationship,evolutionary relationship of CpG units in BDNF promoter Ⅰ and Ⅳ were detected and compared between ASD patients and healthy controls.Results The methylation rate was identified in 17 and 8 CpG units in BDNF promoter][and BDNF promoter Ⅳ.A close correlation distance was detected in BDNF promoter Ⅰ CpG units 4,7,10,35,and BDNF promoter Ⅳ CpG units 11.12,14.BDNF promoter][CpG units 4,7,10,35,and BDNF promoter Ⅳ CpG units 11.12,14 could be clustered.ASD patients had a significant lower methylation rate in BDNF promoter Ⅰ CpG unit 5.6 and Ⅳ CpG units 3 and 15 compare with healthy controls (P＜0.05).Conclusions The DNA methylation rate in BDNF pronoter Ⅰ CpG unit 5.6 and Ⅳ CpG units 3 and 15 may be used as potential biomarkers of ASD.

Objective To compare the effects of transurethral plasmakinetic resection of prostate (TUPKRP) and drug therapy on blood pressure and change of blood pressure rhythm in patients with benign prostatic hyperplasia complicated with hypertension. Methods A total of 103 patients with benign prostatic hyperplasia in the hospital from June 2021 to June 2023 were retrospectively enrolled as study objects. According to different treatment protocols, they were divided into drug therapy group with 47 cases (treated with telmisartan combined with finasteride) and surgical treatment group with 56 cases (treated with telmisartan combined with TUPKRP). Blood pressure levels (24-hour mean diastolic blood pressure, 24-hour mean systolic blood pressure, daytime mean diastolic blood pressure, daytime mean systolic blood pressure, nighttime mean diastolic blood pressure, nighttime mean systolic blood pressure), change of blood pressure rhythm (dipper blood pressure), prostate symptoms, prostate volume, residual urine volume, and sexual function were compared between the two groups before treatment and at 3 and 6 months after treatment. Results The mean blood pressure at different time points in the surgical treatment group was significantly lower than that in the drug therapy group at 3 and 6 months after treatment (P < 0.05). The conversion rates of dipper blood pressure in the surgical treatment group at 3 and 6 months after treatment were 67.86% and 87.50%, which were significantly higher than 40.42% and 68.09% in the drug therapy group (P < 0.05). International Prostate Symptom Score (IPSS), residual urine volume, and prostate volume in the surgical treatment group were significantly lower than those in the drug therapy group at 3 and 6 months after treatment (P < 0.05). There was no significant difference in sexual function between the two groups before treatment and at 3 and 6 months after treatment (P>0.05). Conclusion Telmisartan combined with TUPKRP can reduce blood pressure levels, regulate change of blood pressure rhythm, improve prostate symptoms, reduce prostate volume, and decrease residual urine volume in patients with benign prostatic hyperplasia complicated with hypertension, with minimal impact on sexual function.

Delivery of Health Care ; Technology